This presentation will discuss the development of mGlu5 positive allosteric modulators (PAMs) for the treatment of schizophrenia and related psychiatric disorders, and the caveats encountered during the discovery process.  Importantly, we will discuss the industrial/academic collaboration between JNJ (Janssen) and Vanderbilt, division of labor, intellectual property strategy and challenges in a collaboration of this type and magnitude.  In addition to the logistical aspects, we will also review key scientific findings with novel tool compounds (both pure mGlu5 PAMs and ago-PAMs), from the academic component of the collaboration, which informed the discovery effort and enabled the team to avoid potential pitfalls.   We will also comment on the timeline to the first joint mGlu5 PAM NME, and how an industrial/academic collaboration influenced the timeline.

Development of novel agents for the treatment of Schizophrenia

243rd National Meeting (2012)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.